Purpose: To study the relationship between positioning and rhegmatogenous retinal detachment (RRD) progression before surgery in patients with a fovea-on RRD.
Design: Prospective, single-cohort study.
Subjects: Patients with fovea-on RRD admitted to hospital for bedrest before surgical treatment were recruited.
Methods: Primary outcome was the shortest distance from the foveal center to the retinal detachment border on OCT. Secondary outcomes were measured with a head-mounted positioning sensor and included measures of head movement (linear acceleration and angular velocity) as well as measures of positioning regimen compliance.
Main Outcome Measures: Distance from the fovea to the retinal detachment border.
Results: Overall, 50 patients with fovea-on positioned before RRD repair. One patient (1/50, 2%) progressed from fovea-on to fovea-off. Of the positioning measures, angular velocity demonstrated the strongest correlation with RRD border movement, whereas measures of positioning compliance showed nonsignificant correlation. After defining 3 movement groups: stable, intermediate, and mobile RRDs, we found that a doubling of head movement (angular velocity) correlated with a median RRD border progression of -6 μm/h, -75 μm/h, and -219 μm/h in the 3 groups, respectively.
Conclusions: Rhegmatogenous retinal detachment border movement is correlated to angular velocity of the head, whereas compliance with our current positioning regimen does not have a significant impact on RRD border movement. Not all RRDs progress rapidly toward the fovea, but those that do seem to be highly influenced by head movement. For limiting RRD progression, a reduced movement positioning regimen may be superior to our current gravity-based approach.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.oret.2023.08.016 | DOI Listing |
Purpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Vestn Oftalmol
December 2024
Novosibirsk State Regional Hospital, Novosibirsk, Russia.
Purpose: This study evaluated the impact of phacoemulsification cataract surgery (PE) on anatomical and functional parameters, as well as the regimen and frequency of anti-VEGF injections in patients with neovascular age-related macular degeneration (nAMD) over a long-term period (up to 3 years).
Material And Methods: The study included 117 patients (117 eyes) diagnosed with nAMD and cataract, graded by LOCS: LOCS I (=56; 47.9%), LOCS II (=57; 48.
Retina
December 2024
Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Purpose: To describe the clinical characteristics of macular holes (MH) with an intact bacillary layer.
Methods: This retrospective study analyzed the characteristics and surgical results of 23 eyes with MH and an intact bacillary layer, with or without rhegmatogenous retinal detachment (RRD).
Results: Among the 23 eyes, 11 had only MH, and 12 had concurrent fovea-off RRD.
Retin Cases Brief Rep
October 2024
Retina and Vitreous Department, Hospital Oftalmológico de Sorocaba, Sorocaba, Brazil.
Purpose: To report a case of bilateral ocular cryptococcosis in an immunocompetent patient without neurologic findings.
Methods: Case report.
Results: A 30-year-old healthy Caucasian man presented with painless blurred vision in the left eye.
Graefes Arch Clin Exp Ophthalmol
December 2024
Helen Keller Foundation for Research and Education, Birmingham, AL, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!